2021 Year in Review - Biosimilars

This past year, the COVID-19 pandemic continued to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums.
A real-world retrospective study (Canadian population) showed that patients with HER2-positive neoadjuvant early breast cancer treated with trastuzumab-dkst versus trastuzumab achieved similar pCR rates.
The results of the cost-efficiency analysis within the Centers for Medicare & Medicaid Services Oncology Care Model indicate that switching from reference pegfilgrastim to pegfilgrastim-jmdb provided cost-savings that could potentially be reallocated to food and transportation support.
Preliminary findings of this retrospective study indicate that treatment with bevacizumab reference product may be associated with a higher risk for hypertension and proteinuria, whereas treatment with bevacizumab biosimilars correlated with shorter onset of these adverse events.
A retrospective study conducted in Poland confirmed that treatment with trastuzumab-anns was associated with an acceptable cardiac safety profile, even when switching from trastuzumab reference or when combined with pertuzumab.
The findings from a small, retrospective study suggest that same-day pegfilgrastim-cbqv was a safe and effective alternative to standard administration 24 hours postchemotherapy for the primary and secondary prophylaxis of febrile neutropenia with myelosuppressive chemotherapy in patients with breast cancer.
Real-world evidence indicates robust biosimilar uptake of the first FDA-approved bevacizumab biosimilar, bevacizumab-awwb, across its approved indications, including metastatic colorectal cancer and non–small-cell lung cancer.
The findings of a retrospective observational study on healthcare resource utilization and cost patterns after formulary conversion to a biosimilar indicate that overall results may be driven by behavior at initial formulary switch.
Analysis of real-world trends of biosimilar prescribing from 2019 to 2020 indicated rapid uptake of biosimilars among oncology providers, although the extent of biosimilar prescribing varied among products.
A comprehensive, team-based biosimilar adoption model in a community oncology practice demonstrated successful conversion from brand drugs to biosimilars that was associated with substantial cost-savings.
Page 1 of 3
Results 1 - 10 of 29

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address Line 2
    Zip Code